Taletrectinib (DS-6051b) is a potent, orally active, next-generation selective inhibitor.Taletrectinib showed strong inhibition of recombinant ROS1, NTRK1, NTRK2, and NTRK3 at 0.207, 0.622, 2.28, and 0.98 nM, respectively.Taletrectinib also inhibited ROS1G2032R and other anti-Crizotinib ROS1 mutants.